It could therefore be relevant to develop therapeutic mAbs against LLT1 that could trigger antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or bispecific antibodies and CAR-NK or CAR-T cells to promote tumor cell elimination. Here, CLEC2D is linked to neoplasm.